Publication:
p.X654R IDUA variant among Thai individuals with intermediate mucopolysaccharidosis type I and its residual activity as demonstrated in COS-7 cells

dc.contributor.authorLukana Ngiwsaraen_US
dc.contributor.authorJames R. Ketudat-Cairnsen_US
dc.contributor.authorPhannee Sawangareetrakulen_US
dc.contributor.authorRatana Charoenwattanasatienen_US
dc.contributor.authorVoraratt Champattanachaien_US
dc.contributor.authorChulaluck Kuptanonen_US
dc.contributor.authorSuthipong Pangkanonen_US
dc.contributor.authorThipwimol Tim-Aroonen_US
dc.contributor.authorDuangrurdee Wattanasirichaigoonen_US
dc.contributor.authorJisnuson Svastien_US
dc.contributor.otherSuranaree University of Technologyen_US
dc.contributor.otherChulabhorn Research Instituteen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherQueen Sirikit National Institute of Child Healthen_US
dc.date.accessioned2019-08-23T10:34:15Z
dc.date.available2019-08-23T10:34:15Z
dc.date.issued2018-05-01en_US
dc.description.abstract© 2017 John Wiley & Sons Ltd/University College London Background: Mucopolysaccharidosis type I (MPS I) is a rare autosomal-recessive disorder caused by defects in alpha-L-iduronidase (IDUA), a lysosomal enzyme encoded by the IDUA gene. Herein, we characterized IDUA mutations underlying mucopolysaccharidosis type I intermediate form (Hurler–Scheie syndrome) and its molecular pathogenic mechanisms. Methods: Clinical data, activity of the IDUA enzyme in leukocytes, and a mutation of the IDUA gene were analyzed. Pathogenesis associated with an IDUA mutation was further investigated by evaluating the mutant cDNA sequence, protein expression and activity in COS-7 cells. Results: Five unrelated patients were identified to have clinical diagnosis of intermediate form of MPS I (Hurler–Scheie) and exhibited low-to-absent levels of leukocyte IDUA activity. Genetic analysis revealed homozygous c.*1T>C (p.X654R) mutation in two patients and compound heterozygosity between the c.*1T>C and another allele including c.265G>A (p.R89Q), c.935G>A (p.W312X), or c.1138 C>T (p.Q380X), each in a single patient. Sequencing the 3′RACE product of the c.*1T>C (p.X654R) allele indicated a 38-amino acids elongation of the mutant protein. COS-7 cells expressing IDUA with the mutations exhibited extremely low levels or complete absence of enzyme activity compared to wild-type IDUA. Western blot analysis detected no protein in p.W312X and p.Q380X samples, while an elevated molecular mass and a different pattern of protein bands were found in p.X654R specimen compared with the wild type IDUA. Conclusions: Mutational spectrum underlying intermediate MPS I is expanded. Our data suggest that the p.X654R is an intermediate IDUA mutant allele with residual enzyme activity. It can lead to intermediate or milder form of MPS I depending on another associated allele.en_US
dc.identifier.citationAnnals of Human Genetics. Vol.82, No.3 (2018), 150-157en_US
dc.identifier.doi10.1111/ahg.12236en_US
dc.identifier.issn14691809en_US
dc.identifier.issn00034800en_US
dc.identifier.other2-s2.0-85039173561en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/45181
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85039173561&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titlep.X654R IDUA variant among Thai individuals with intermediate mucopolysaccharidosis type I and its residual activity as demonstrated in COS-7 cellsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85039173561&origin=inwarden_US

Files

Collections